R01CA033193

IARC MONOGRAPHS ON THE IDENTIFICATION OF CARCINOGENIC HAZARDS TO HUMANS - PROJECT SUMMARY/ABSTRACT SINCE 1971, THE IARC MONOGRAPHS ON THE IDENTIFICATION OF CARCINOGENIC HAZARDS TO HUMANS HAS PROVIDED AN EVIDENCE-BASED APPROACH TO IDENTIFYING THE PREVENTABLE CAUSES OF HUMAN CANCER. ORGANIZATIONS WORLDWIDE RELY ON THE IARC MONOGRAPHS AS A TRUSTWORTHY SOURCE OF CARCINOGENICITY EVALUATIONS IN THEIR EFFORTS TO CONTROL CANCER. AGENTS EVALUATED BY THE MONOGRAPHS ENCOMPASS CHEMICALS, PHYSICAL AND BIOLOGICAL AGENTS, COMPLEX MIXTURES, OCCUPATIONAL EXPOSURE CIRCUMSTANCES, AND OTHER EXPOSURES OF EVERYDAY LIFE. TO DATE, 1021 AGENTS HAVE BEEN EVALUATED, WITH 121 CLASSIFIED AS “CARCINOGENIC”, 89 AS “PROBABLY CARCINOGENIC”, AND 315 AS “POSSIBLY CARCINOGENIC” TO HUMANS. AGENTS ARE SELECTED FOR EVALUATION BASED ON EVIDENCE OF HUMAN EXPOSURE AND OF CARCINOGENICITY, AND PUBLIC HEALTH IMPORTANCE. MONOGRAPHS ARE DEVELOPED BY INDEPENDENT GLOBAL EXPERTS WITHOUT CONFLICTS OF INTEREST. EACH MONOGRAPH INCLUDES SYSTEMATIC REVIEWS OF THE PERTINENT SCIENTIFIC LITERATURE COVERING THREE UNIQUE STREAMS OF EVIDENCE (CANCER IN HUMANS, CANCER IN EXPERIMENTAL ANIMALS, AND MECHANISTIC EVIDENCE). THE

Centre International De Recherche Sur Le Cancer

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

France

Foreign

Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program (R01 Clinical Trial Not Allowed) (RFA-CA-20-045)

Amendment Since initial award the total obligations have increased 454% from $880,253 to $4,878,214.